Index -
P/E -
EPS (ttm) -2.68
Insider Own 0.54%
Shs Outstand 126.49M
Perf Week 7.21%
Market Cap 19.52B
Forward P/E -
EPS next Y -1.95
Insider Trans -10.11%
Shs Float 125.80M
Perf Month -1.10%
Income -332.08M
PEG -
EPS next Q -1.06
Inst Own 93.06%
Short Float 1.99%
Perf Quarter -10.37%
Sales 2.00B
P/S 9.74
EPS this Y -2.58%
Inst Trans 0.95%
Short Ratio 3.07
Perf Half Y -7.78%
Book/sh -1.73
P/B -
EPS next Y 46.08%
ROA -9.20%
Short Interest 2.50M
Perf Year -24.86%
Cash/sh 18.75
P/C 8.23
EPS next 5Y -
ROE -1500.66%
52W Range 141.98 - 218.88
Perf YTD -19.37%
Dividend Est. -
P/FCF 152.72
EPS past 5Y 14.18%
ROI -13.97%
52W High -29.49%
Beta 0.30
Dividend TTM -
Quick Ratio 3.07
Sales past 5Y 97.61%
Gross Margin 83.95%
52W Low 8.70%
ATR (14) 4.41
Dividend Ex-Date -
Current Ratio 3.17
EPS Y/Y TTM 69.50%
Oper. Margin -8.78%
RSI (14) 59.89
Volatility 3.48% 2.74%
Employees 2100
Debt/Eq -
Sales Y/Y TTM 75.20%
Profit Margin -16.58%
Recom 1.80
Target Price 218.58
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 62.74%
Payout -
Rel Volume 0.43
Prev Close 151.22
Sales Surprise 15.50%
EPS Surprise 53.41%
Sales Q/Q 54.82%
Earnings May 02 BMO
Avg Volume 813.62K
Price 154.33
SMA20 4.42%
SMA50 3.10%
SMA200 -9.79%
Trades
Volume 353,436
Change 2.06%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-16-24 Downgrade
Goldman
Buy → Neutral
$173
Feb-15-24 Initiated
Wolfe Research
Peer Perform
Dec-08-23 Initiated
Wells Fargo
Equal Weight
$171
Dec-08-23 Initiated
Wells Fargo
Equal Weight
Oct-11-23 Downgrade
Oppenheimer
Outperform → Perform
Sep-29-23 Initiated
Raymond James
Outperform
$208
May-05-23 Upgrade
BMO Capital Markets
Market Perform → Outperform
$200 → $250
Apr-26-23 Initiated
SMBC Nikko
Neutral
$220
Mar-21-23 Initiated
Bernstein
Outperform
$243
Jan-18-23 Initiated
Canaccord Genuity
Buy
$310
Sep-09-22 Resumed
Morgan Stanley
Equal-Weight
$222
Jul-13-22 Initiated
Cantor Fitzgerald
Neutral
$175
Jun-27-22 Downgrade
Guggenheim
Buy → Neutral
Jun-07-22 Initiated
William Blair
Outperform
Apr-25-22 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$210 → $178
Mar-01-22 Initiated
Citigroup
Buy
$223
Feb-03-22 Upgrade
Guggenheim
Neutral → Buy
$170
Jan-03-22 Upgrade
Piper Sandler
Neutral → Overweight
$181 → $208
Nov-22-21 Upgrade
RBC Capital Mkts
Sector Perform → Outperform
$144 → $225
Nov-22-21 Upgrade
Goldman
Neutral → Buy
$273
Show Previous Ratings
May-07-24 09:12AM
08:00AM
May-03-24 01:01PM
12:29PM
10:48AM
03:11AM
Loading…
03:11AM
01:06AM
May-02-24 12:53PM
10:00AM
09:10AM
09:04AM
08:08AM
(Associated Press Finance)
08:00AM
May-01-24 08:10AM
Apr-30-24 09:15AM
07:00AM
Loading…
07:00AM
Apr-29-24 09:49AM
Apr-25-24 10:01AM
Apr-18-24 08:00AM
Apr-08-24 08:44AM
Apr-07-24 08:00AM
Mar-20-24 08:00AM
Mar-17-24 08:50AM
Mar-13-24 07:30AM
Mar-06-24 11:26AM
Mar-05-24 09:06AM
08:27AM
07:52AM
07:30AM
Feb-27-24 08:30AM
08:45AM
Loading…
Feb-24-24 08:45AM
Feb-21-24 12:06PM
Feb-16-24 12:08PM
09:46AM
01:55AM
(Thomson Reuters StreetEvents)
12:02AM
Feb-15-24 12:39PM
10:30AM
08:37AM
08:17AM
(Associated Press Finance)
08:00AM
06:54AM
Feb-13-24 07:48PM
Feb-12-24 09:16AM
Feb-08-24 10:00AM
Feb-05-24 05:02PM
Jan-30-24 03:02PM
Jan-29-24 08:00AM
Jan-09-24 08:05AM
Jan-08-24 01:49PM
Jan-07-24 06:00PM
Jan-02-24 07:30AM
Dec-22-23 02:07AM
Dec-19-23 11:41AM
Dec-13-23 07:30AM
Dec-07-23 07:53PM
Dec-06-23 08:00AM
Nov-30-23 08:00AM
Nov-11-23 04:00PM
Nov-09-23 09:25AM
Nov-08-23 09:55AM
Nov-07-23 08:00AM
Nov-04-23 01:08PM
Nov-03-23 11:47AM
11:06AM
Nov-02-23 10:09AM
10:00AM
08:12AM
(Associated Press Finance)
08:00AM
Oct-26-23 02:00PM
10:02AM
Oct-25-23 05:19PM
11:05AM
Oct-19-23 07:28PM
10:01AM
08:00AM
Oct-12-23 08:24AM
Oct-10-23 10:24AM
Oct-09-23 04:35PM
04:08PM
(Investor's Business Daily)
10:34AM
10:19AM
(Investor's Business Daily)
07:49AM
07:36AM
07:30AM
Oct-08-23 06:29AM
Oct-06-23 07:00AM
Sep-20-23 12:12PM
Sep-14-23 04:07PM
(Investor's Business Daily) -8.78%
09:36AM
Sep-13-23 06:24PM
04:57PM
08:08AM
07:00AM
Sep-08-23 09:58AM
06:52AM
Sep-07-23 11:30AM
07:22AM
07:08AM
07:00AM
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
SHARP PHILLIP A Director Feb 29 '24 Option Exercise 59.25 30,000 1,777,500 30,000 Mar 01 04:12 PM SHARP PHILLIP A Director Feb 29 '24 Sale 151.34 30,000 4,540,071 0 Mar 01 04:12 PM Greenstreet Yvonne Chief Executive Officer Feb 28 '24 Sale 155.31 2,932 455,357 48,128 Feb 29 04:18 PM Garg Pushkal CMO & EVP Dev & Med Affairs Feb 28 '24 Sale 155.30 574 89,145 8,666 Feb 29 04:17 PM Poulton Jeffrey V. EVP, Chief Financial Officer Feb 28 '24 Sale 155.30 574 89,145 19,478 Feb 29 04:18 PM Tanguler Tolga EVP, Chief Commercial Officer Feb 28 '24 Sale 155.30 501 77,805 5,236 Feb 29 04:18 PM Franchini Indrani Lall EVP, CLO & Secretary Feb 28 '24 Sale 155.30 329 51,094 4,133 Feb 29 04:16 PM Franchini Indrani Lall EVP, CLO & Secretary Feb 27 '24 Option Exercise 0.00 878 0 4,462 Feb 29 04:16 PM Greenstreet Yvonne Chief Executive Officer Feb 27 '24 Option Exercise 0.00 5,921 0 51,060 Feb 29 04:18 PM Tanguler Tolga EVP, Chief Commercial Officer Feb 27 '24 Option Exercise 0.00 1,667 0 5,737 Feb 29 04:18 PM Poulton Jeffrey V. EVP, Chief Financial Officer Feb 27 '24 Option Exercise 0.00 1,908 0 20,052 Feb 29 04:18 PM Garg Pushkal CMO & EVP Dev & Med Affairs Feb 27 '24 Option Exercise 0.00 1,908 0 9,240 Feb 29 04:17 PM Greenstreet Yvonne Chief Executive Officer Feb 16 '24 Sale 148.06 7,030 1,040,885 45,139 Feb 20 04:07 PM Garg Pushkal CMO & EVP Dev & Med Affairs Feb 16 '24 Sale 148.06 1,308 193,666 7,332 Feb 20 04:09 PM Tanguler Tolga EVP, Chief Commercial Officer Feb 16 '24 Sale 148.06 1,009 149,397 4,070 Feb 20 04:08 PM Poulton Jeffrey V. EVP, Chief Financial Officer Feb 16 '24 Sale 148.06 1,007 149,099 18,144 Feb 20 04:08 PM Franchini Indrani Lall EVP, CLO & Secretary Feb 02 '24 Sale 170.99 1,591 272,050 3,584 Feb 05 04:05 PM Franchini Indrani Lall EVP, CLO & Secretary Feb 01 '24 Option Exercise 0.00 5,175 0 5,175 Feb 05 04:05 PM BONNEY MICHAEL W Director Dec 27 '23 Option Exercise 96.45 30,000 2,893,500 46,029 Dec 29 04:03 PM BONNEY MICHAEL W Director Dec 27 '23 Sale 195.00 30,000 5,850,000 16,029 Dec 29 04:03 PM Garg Pushkal CMO & EVP Dev & Med Affairs Aug 07 '23 Sale 183.89 4,166 766,083 4,345 Aug 07 06:05 PM Vaishnaw Akshay President Aug 04 '23 Sale 185.85 4,057 753,986 22,774 Aug 07 06:04 PM Greenstreet Yvonne Chief Executive Officer Aug 04 '23 Sale 185.85 4,057 753,986 35,216 Aug 07 06:04 PM Garg Pushkal CMO & EVP Dev & Med Affairs Aug 04 '23 Sale 185.85 3,461 643,223 8,511 Aug 07 06:05 PM Poulton Jeffrey V. EVP, Chief Financial Officer Aug 04 '23 Sale 185.85 3,460 643,037 15,873 Aug 07 06:05 PM BONNEY MICHAEL W Director Aug 03 '23 Sale 185.38 6,448 1,195,310 16,029 Aug 04 04:02 PM BONNEY MICHAEL W Director Aug 02 '23 Option Exercise 0.00 22,477 0 22,477 Aug 04 04:02 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite